MARKET

PTE

PTE

PolarityTE
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4801
-0.0029
-0.60%
Opening 10:29 01/27 EST
OPEN
0.5000
PREV CLOSE
0.4830
HIGH
0.5200
LOW
0.4745
VOLUME
171.74K
TURNOVER
--
52 WEEK HIGH
1.990
52 WEEK LOW
0.3800
MARKET CAP
39.34M
P/E (TTM)
-0.9511
1D
5D
1M
3M
1Y
5Y
PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.
Zacks · 01/19 16:37
PolarityTE gets US FDA clearance to begin phase 3 trial of SkinTE for chronic ulcers
PolarityTE (PTE -0.4%) said the U.S. Food and Drug Administration approved its investigational new drug (IND) to begin a phase 3 trial of SkinTE to treat chronic cutaneous ulcers. In December
Seekingalpha · 01/18 20:11
FDA Approves PolarityTE's Phase 3 Study Of SkinTE In Chronic Cutaneous Ulcer
The 
Benzinga · 01/18 17:40
BRIEF-Polarityte Announces U.S. FDA Approval Of IND For Pivotal Phase 3 Study Of Skinte® For Chronic Cutaneous Ulcer
reuters.com · 01/18 13:17
PolarityTE Announces U.S. FDA Approval Of IND For Pivotal Phase 3 Study Of SkinTE To Support Chronic Cutaneous Ulcer Indication
PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new
Benzinga · 01/18 13:05
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application for the evaluatio...
PR Newswire · 01/18 13:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 01/03 13:10
PolarityTE submits complete response to FDA's clinical hold for SkinTE application
PolarityTE (NASDAQ:PTE) has submitted its complete response to the FDA's clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE with a proposed indication for chronic cutaneous ulcers. Shares up
Seekingalpha · 12/20/2021 14:18
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PTE. Analyze the recent business situations of PolarityTE through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PTE stock price target is 2.250 with a high estimate of 2.500 and a low estimate of 2.000.
High2.500
Average2.250
Low2.000
Current 0.4801
EPS
Actual
Estimate
-0.21-0.16-0.10-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 105
Institutional Holdings: 13.55M
% Owned: 16.54%
Shares Outstanding: 81.93M
TypeInstitutionsShares
Increased
11
688.18K
New
5
237.39K
Decreased
12
1.05M
Sold Out
8
230.47K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.05%
Pharmaceuticals & Medical Research
+1.40%
Key Executives
Non-Executive Chairman/Independent Director
Peter Cohen
President/Chief Executive Officer
Richard Hague
Chief Financial Officer
Jacob Patterson
Executive Vice President/General Counsel/Secretary
Cameron Hoyler
Other
Ryan Mathis
Director
David Seaburg
Independent Director
Willie Bogan
Independent Director
Jeff Dyer
Independent Director
Chris Nolet
Independent Director
Jessica Shen
Declaration Date
Dividend Per Share
Ex-Div Date
01/04/2016
Dividend USD 0.33550232
01/19/2016
About PTE
PolarityTE, Inc. is a biotechnology company. The Company is focused on developing regenerative tissue products and biomaterials. It also operates a laboratory testing and clinical research business using equipment, personnel, and facilities it acquired to advance its development of regenerative tissue products. Its first regenerative tissue product is SkinTE, which is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need for treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. The Company's development projects include SkinTE Cryo, SkinTE point-of-care device, PTE 11000, and others.

Webull offers kinds of Polarityte Inc stock information, including NASDAQ:PTE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTE stock methods without spending real money on the virtual paper trading platform.